This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters

A Case of Hypomania Induced by Lamotrigine Augmentation

A Case of Hypomania Induced by Lamotrigine Augmentation

To the Editor: The induction of mania or hypomania has been infrequently reported for anticonvulsants, but has been described for divalproex,1 zonisamide,2 topiramate,3,4 gabapentin,5,6 and lamotrigine—most often in the context of the treatment of bipolar depression.7-10 To our knowledge, lamotrigine-induced hypomania has been reported in unipolar depression on only one occasion, when used as an augmentation strategy with bupropion for depression in a 23-year-old woman.11 In that single case report, the patient initially experienced an improved mood on lower doses of lamotrigine (ie, 25 mg and 50 mg) but, 1 week after an increase to 75 mg/d, developed hypomania. When the dosage of lamotrigine was decreased to 50 mg/d, the hypomanic symptoms subsided.

In the following case report, we describe a second case of hypomania that developed when lamotrigine was prescribed as an augmentation strategy in a patient with unipolar depression.

Case report. Ms A, a 31-year-old woman, initially presented in 2008 for the treatment of major depressive disorder (per DSM-IV criteria) characterized by dysphoric mood, anhedonia, decreased energy/fatigue, impaired concentration, hypersomnia, psychomotor slowing, low self-esteem, feelings of hopelessness, and general dissatisfaction with life. At evaluation, the patient denied any manic episodes, appetite/weight changes, suicidal ideation, drug/alcohol abuse, or psychotic symptoms. The family history indicated depression as well as antidepressant treatment in mother and father. Several depressive symptoms had been present for longer than 2 years, confirming the presence of DSM-IV dysthymic disorder, and the patient evidenced some obsessive-compulsive personality features as well.

Ms A had been on treatment with a number of antidepressants in the past, but at the time of lamotrigine exposure had been on duloxetine 60 mg/d for 1 year. (She had also received several past augmentation strategies including bupropion, buspirone, gabapentin, and topiramate.) Because she was experiencing some mood slippage, lamotrigine was initiated in June 2010 as an augmentation strategy. Lamotrigine was started at 12.5 mg/d and then increased by 12.5 mg every 2 weeks to 50 mg/d. Initially, the patient experienced an improvement in mood. However, 2 weeks after she reached a dose of 50 mg/d, the patient reported feeling “hyper.” Ms A could not sleep but did not feel a need for sleep, was easily distracted (eg, would jump from task to task without completion), could not engage in sedentary activities such as watching television, started talking faster (a client teased her about excessive coffee ingestion), experienced excessive psychomotor activation (eg, she started working out twice daily), became inappropriately flirtatious on one occasion, and ran through a fountain and sustained a minor injury. A diagnosis of hypomania was made and, as in the preceding case report, the lamotrigine dose was decreased (to 37.5 mg/d in this case), leading to the recession of symptoms.

The induction of hypomania by lamotrigine in a patient with unipolar depression prompts clinicians to be alert to such paradoxical phenomena when prescribing anticonvulsants. Ironically, the anticonvulsants, many of which have formal indications by the US Food and Drug Administration for the treatment of mania/hypomania, can on rare occasion induce these unexpected symptoms.

References

1. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord. 2005;85(3):259-266. PubMed doi:10.1016/j.jad.2004.09.009

2. Ghaemi SN, Zablotsky B, Filkowski MM, et al. An open prospective study of zonisamide in acute bipolar depression. J Clin Psychopharmacol. 2006;26(4):385-388. PubMed doi:10.1097/01.jcp.0000227702.72117.f5

3. Okuyucu E, Melek IM, Duman T, et al. Hypomania complicating topiramate therapy for migraine prophylaxis. Eur J Neurol. 2007;14(3):e6. PubMed doi:10.1111/j.1468-1331.2006.01589.x

4. Kaplan M. Hypomania with topiramate. J Clin Psychopharmacol. 2005;25(2):196-197. PubMed doi:10.1097/01.jcp.0000155828.82456.68

5. Hauck A, Bhaumik S. Hypomania induced by gabapentin. Br J Psychiatry. 1995;167(4):549. PubMed doi:10.1192/bjp.167.4.549a

6. Short C, Cooke L. Hypomania induced by gabapentin. Br J Psychiatry. 1995;166(5):679-680. PubMed doi:10.1192/bjp.166.5.679b

7. McElroy SL, Zarate CA, Cookson J, et al. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry. 2004;65(2):204-210. PubMed doi:10.4088/JCP.v65n0210

8. Raskin S, Teitelbaum A, Zislin J, et al. Adjunctive lamotrigine as a possible mania inducer in bipolar patients. Am J Psychiatry. 2006;163(1):159-160. PubMed doi:10.1176/appi.ajp.163.1.159-a

9. Schaffer A, Zuker P, Levitt A. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord. 2006;96(1-2):95-99. PubMed doi:10.1016/j.jad.2006.05.023

10. van der Loos ML, Mulder PG, Hartong EG, et al. LamLit Study Group. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(2):223-231. PubMed doi:10.4088/JCP.08m04152

11. Margolese HC, Beauclair L, Szkrumelak N, et al. Hypomania induced by adjunctive lamotrigine. Am J Psychiatry. 2003;160(1):183-184. PubMed doi:10.1176/appi.ajp.160.1.183-a

Randy A. Sansone, MD

Randy.sansone@khnetwork.org

Lori A. Sansone, MD

Author affiliations: Departments of Psychiatry and Internal Medicine, Wright State University School of Medicine, Dayton; Department of Psychiatry Education, Kettering Medical Center, Kettering (Dr R. Sansone); and Primary Care Clinic, Wright-Patterson Air Force Base, Dayton (Dr L. Sansone), Ohio.

Potential conflicts of interest: None reported.

Funding/support: None reported.

Disclaimer: The views and opinions expressed in this article are those of the authors and do not reflect the official policy or position of the US Air Force, Department of Defense, or US Government.

Published online: February 24, 2011 (doi:10.4088/PCC.10l01064).

Related Articles

Volume: 13

Quick Links: Schizophrenia and Schizoaffective Disorders , Side Effects

$40.00

Buy this Article as a PDF

References